|
1
|
Levin VA, Mendelssohn ND, Chan J, Stovall
MC, Peak SJ, Yee JL, Hui RL and Chen DM: Impact of bevacizumab
administered dose on overall survival of patients with progressive
glioblastoma. J Neurooncol. 122:145–150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al:
Phase II trial of single-agent bevacizumab followed by bevacizumab
plus irinotecan at tumor progression in recurrent glioblastoma. J
Clin Oncol. 27:740–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taal W, Oosterkamp HM, Walenkamp AM,
Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D,
de Vos FY, et al: Single-agent bevacizumab or lomustine versus a
combination of bevacizumab plus lomustine in patients with
recurrent glioblastoma (BELOB trial): A randomised controlled phase
2 trial. Lancet Oncol. 15:943–953. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu KV and Bergers G: Mechanisms of evasive
resistance to anti-VEGF therapy in glioblastoma. CNS Oncol.
2:49–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Piao Y, Liang J, Holmes L, Henry V, Sulman
E and de Groot JF: Acquired resistance to anti-VEGF therapy in
glioblastoma is associated with a mesenchymal transition. Clin
Cancer Res. 19:4392–4403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen PY, Macdonald DR, Reardon DA,
Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert
MR, Lassman AB, et al: Updated response assessment criteria for
high-grade gliomas: Response assessment in neuro-oncology working
group. J Clin Oncol. 28:1963–1972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lamszus K, Ulbricht U, Matschke J,
Brockmann MA, Fillbrandt R and Westphal M: Levels of soluble
vascular endothelial growth factor (VEGF) receptor 1 in astrocytic
tumors and its relation to malignancy, vascularity, and VEGF-A.
Clin Cancer Res. 9:1399–1405. 2003.PubMed/NCBI
|
|
11
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Winkler F, Kozin SV, Tong RT, Chae SS,
Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E,
et al: Kinetics of vascular normalization by VEGFR2 blockade
governs brain tumor response to radiation: Role of oxygenation,
angiopoietin-1, and matrix metalloproteinases. Cancer Cell.
6:553–563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shrimali RK, Yu Z, Theoret MR, Chinnasamy
D, Restifo NP and Rosenberg SA: Antiangiogenic agents can increase
lymphocyte infiltration into tumor and enhance the effectiveness of
adoptive immunotherapy of cancer. Cancer Res. 70:6171–6180. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van der Veldt AA, Lubberink M, Bahce I,
Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J,
Windhorst AD, Postmus PE, et al: Rapid decrease in delivery of
chemotherapy to tumors after anti-VEGF therapy: Implications for
scheduling of anti-angiogenic drugs. Cancer Cell. 21:82–91. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Batchelor TT, Reardon DA, de Groot JF,
Wick W and Weller M: Antiangiogenic therapy for glioblastoma:
Current status and future prospects. Clin Cancer Res. 20:5612–5619.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pope WB, Lai A, Nghiemphu P, Mischel P and
Cloughesy TF: MRI in patients with high-grade gliomas treated with
bevacizumab and chemotherapy. Neurology. 66:1258–1260. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ananthnarayan S, Bahng J, Roring J,
Nghiemphu P, Lai A, Cloughesy T and Pope WB: Time course of imaging
changes of GBM during extended bevacizumab treatment. J Neurooncol.
88:339–347. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iwamoto FM, Abrey LE, Beal K, Gutin PH,
Rosenblum MK, Reuter VE, DeAngelis LM and Lassman AB: Patterns of
relapse and prognosis after bevacizumab failure in recurrent
glioblastoma. Neurology. 73:1200–1206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gaspar LE, Fisher BJ, Macdonald DR, LeBer
DV, Halperin EC, Schold SC Jr and Cairncross JG: Supratentorial
malignant glioma: Patterns of recurrence and implications for
external beam local treatment. Int J Radiat Oncol Biol Phys.
24:55–57. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gallego Pérez-Larraya J, Lahutte M,
Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C,
Guillevin R, Sanson M, Hoang-Xuan K and Delattre JY: Response
assessment in recurrent glioblastoma treated with
irinotecan-bevacizumab: Comparative analysis of the Macdonald,
RECIST, RANO, and RECIST + F criteria. Neuro Oncol. 14:667–673.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nowosielski M, Wiestler B, Goebel G,
Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M and
Radbruch A: Progression types after antiangiogenic therapy are
related to outcome in recurrent glioblastoma. Neurology.
82:1684–1692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Du R, Lu KV, Petritsch C, Liu P, Ganss R,
Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z and Bergers G:
HIF1alpha induces the recruitment of bone marrow-derived vascular
modulatory cells to regulate tumor angiogenesis and invasion.
Cancer Cell. 13:206–220. 2008. View Article : Google Scholar : PubMed/NCBI
|
